ClinicalTrials.gg
RecruitingNCT04429542Updated Oct 6, 2026

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

A Phase 1 interventional study of BCA101 and Pembrolizumab in Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal and Colorectal Cancer, sponsored by Bicara Therapeutics. Recruiting at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Bicara Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.
Updated Oct 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
473
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
44th of 993
473 · median 41
Started
2020
with 69 others
Phase 1
362 of 1,099
71 open now
Primary completion
2027-10
later than 175 of 346 live
Registered
692nd of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 44th largest by planned enrollment of the 993 interventional ones that give a count, is one of 70 that started in 2020, is one of 362 in phase 1, reaches primary completion later than 175 of the 346 other live ones, and was the 692nd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

Read the detailed description

This is a Phase 1/1b, open-label study, which consists of dose escalation parts (Part A) followed by expansion cohorts (Part B) for both single agent BCA101 and combination BCA101 plus pembrolizumab.

The study population in dose escalation (Part A) of single agent BCA101 consists of subjects with EGFR-driven advanced solid tumors refractory to standard of care or for whom no standard of care is available. Dose escalation (Part A) of combination BCA101 and pembrolizumab consists of subjects with either Squamous Cell Carcinoma of the Head and Neck (HNSCC) or Squamous Cell Carcinoma of the Anal Canal (SCCAC) whose tumors are refractory to standard of care or for whom no standard of care is available.

Once the maximum tolerated dose (MTD) / recommended dose (RD) of single agent BCA101 is determined, the study will continue with expansion cohorts (Part B) with select tumor types. Expansion cohorts for single agent BCA101 will include cutaneous squamous cell carcinoma. Planned expansion cohorts for the combination of BCA101 and pembrolizumab include: 1) HNSCC and 2) SCCAC.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Anal Canal
  • Colorectal Cancer
  • Squamous Cell Carcinoma of the Lung
  • EGFR Amplification
  • Epithelial Ovarian Cancer
  • Pancreas Cancer
  • Cutaneous Squamous Cell Carcinoma
  • Head and Neck Neoplasms
  • Carcinoma, Squamous Cell
  • Squamous Cell Carcinoma of Head and Neck

Keywords

  • TGFβ
  • EGFR
  • pembrolizumab
  • ficerafusp alfa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must have amendable to and be willing to undergo both a pre-treatment and on-treatment biopsy, as well as provide archival tumor if available from the primary tumor (a paraffin embedded tumor tissue block sufficient to obtain at least 10 sections of 4 to 5 micrometer thickness).
  • Patient must have a performance status of ≤1 on the Performance Scale.
  • Patients must have evaluable or measurable disease (computed tomography [CT]/magnetic resonance imaging [MRI] scans performed within 21 days before the screening visit are acceptable) demonstrating measurable disease, i.e., at least 1 unidimensional measurable lesion as defined by , Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors ().
  • Tumor eligibility:

PART B (Cohort expansion):

  1. Single agent BCA101 - patients with the following tumor type will be eligible:

    • Expansion Cohort 1: Cutaneous Squamous Cell Carcinoma (CSCC) - i. patients must have received (or been intolerant to or ineligible for) prior therapy in the or locally advanced setting.

    ii. No prior history of treatment with anti-EGFR antibodies in the unresectable/metastatic setting (prior treatment with radiotherapy in the setting is allowed).

  2. Combination BCA101 and pembrolizumab - patients with the following tumor types will be eligible:

    • Expansion Cohort 2: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) equal to or greater than 1, as determined by an CLIA-approved laboratory test. Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Participants may not have a primary tumor site of nasopharynx (any histology).

    i. Patients must have no prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally advanced disease) or prior history of immune checkpoint inhibitors with the exception of neoadjuvant therapy (>6 months prior to study drug initiation). No prior history of anti-EGFR antibodies (with the exception of radiosensitizing agents and multimodal treatment for locally advanced disease).

    ii. Patients must provide tissue for PD-L1 biomarker analysis from a core or excisional biopsy (fine needle aspirate is not sufficient): A newly obtained biopsy (within 90 days prior to start of study treatment) is preferred but an archival sample is acceptable.

    iii. Patients must have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer

    • Expansion Cohort 3: Squamous Carcinoma of the Anal Canal (SCAC), locally advanced/unresectable or metastatic.

      i. Patients must have received (or been intolerant to or ineligible for) at least 1 and received no more than 2 prior lines of systemic treatments for treatment of unresectable and/or metastatic disease. No prior history of immune checkpoint inhibitors.

    • Expansion Cohort 5: Squamous Non-Small Cell Lung Cancer (SqNSCLC) i. Patients must have a or cytologically confirmed diagnosis of stage IV (AJCC 8th edition) squamous NSCLC. Patients with mixed histology (e.g., adenosquamous) are not allowed.

    ii. Patients must have progressed on one prior systemic therapy in the metastatic setting.

    iii. No prior history of treatment with anti-EGFR antibodies in the metastatic setting.

    • Expansion Cohort 6: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) less than 1, as determined by PD-L1 IHC 22C3 pharmDx.
  3. Randomized to either ficerafusp alfa alone or in combination with pembrolizumab • Expansion Cohort 9: Colorectal cancer (CRC) i. Patients must have received at least 2 and no more than 3 prior lines of systemic therapy including two standard treatment regimens.

Exclusion criteria

Exclusion Criteria:

  • For Part A: Exposure to anti-EGFR antibodies within 4 weeks of the first dose of study drug.
  • Prior treatment with any anti-TGFβ therapy.
  • Prior history of Grade ≥ 2 intolerance or reaction to cetuximab or other anti-EGFR therapy or other murine proteins or prior discontinuation of therapy in the setting of toxicity related to treatment.
  • Pregnant or breastfeeding women.
  • Any condition requiring systemic treatment with either (>10 mg daily of prednisone or equivalent) or other medication within 14 days prior to the first dose of study drug, with the exception of topical, intranasal, intrabronchial, or ocular steroids.
  • Known history of a hematologic (or solid tumor other than the ones indicated for this study), unless the patient has undergone potentially curative therapy with no evidence of that disease for 2 years. Does not include tumors with a negligible risk of or death (e.g. adequately treated basal or squamous cell carcinoma, stage 1 prostate cancer, or carcinoma in situ of the cervix or carcinoma in situ of the breast). Subjects enrolling in the CSCC cohort may have chronic lymphocytic leukemia as long as the patient is not on active treatment.
  • Known cases of (HIV) are excluded if patients have a CD4+ T-cell (CD4+) count \<250 cells/uL. To ensure that effective antiretroviral therapy (ART) is tolerated and that toxicities are not confused with drug toxicities, trial participants should be on established ART for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment.
  • Patients with chronic infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment
  • Patients with a known history of who have not completed curative antiviral treatment or have a HCV viral load above the limit of quantification
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
473 participants (estimated)

Study arms

  • Experimental
    BCA101 Monotherapy

    Route: IV Infusion Frequency: QW Current Dose: 1500mg

    Drug: BCA101

  • Experimental
    BCA101 + pembrolizumab

    Route: IV Infusion Frequency: Q3W Dose: 200mg

    Drug: BCA101 · Drug: Pembrolizumab

Interventions

  • DrugBCA101

    EGFR/TGFβ fusion monoclonal antibody

    Also known as: Ficerafusp alfa

  • anti-PD-1

06

What researchers measure

Primary outcomes

  1. Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs

    Incidence and severity of AEs and SAEs

    Time frame: 24 months

  2. Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs

    Incidence and severity of AEs and SAEs

    Time frame: 24 months

  3. Incidence of Dose Limiting Toxicities (DLTs)

    Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.

    Time frame: 21 days

Secondary outcomes

  1. Objective Response Rate

    Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST

    Time frame: 24 months

  2. Clinical Benefit Rate

    Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST

    Time frame: 24 months

  3. Progression free survival

    Determine PFS in each part of the study, per RECIST v1.1 and iRECIST

    Time frame: 24 months

  4. Duration of Response

    Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST

    Time frame: 24 months

  5. Overall Survival

    Determine survival rates in each part of the study.

    Time frame: 24 months

  6. AUC of BCA101 and pembrolizumab

    AUC

    Time frame: 24 months

  7. Cmax of BCA101 and pembrolizumab

    Cmax

    Time frame: 24 months

  8. Tmax of BCA101 and pembrolizumab

    Tmax

    Time frame: 24 months

  9. Concentration vs time profile of BCA101 and pembrolizumab

    Ctrough

    Time frame: 24 months

  10. Half-life of BCA101 and pembrolizumab

    Half-life

    Time frame: 24 months

  11. Immunogenicity of BCA101 and pembrolizumab

    Incidence and titer of anti-drug-antibodies

    Time frame: 24 months

07

Study locations

21 of 21 sites recruiting
  • Moores Cancer Center UC San Diego Health
    La Jolla, California 92093, United States
    Recruiting
    • Moores UCSD Cancer Center Clinical Trials Office · Contactd1ghosh@health.ucsd.edu · 858-822-5354
    • Assuntina Sacco, MD · Principal investigator
  • Keck School of Medicine of USC
    Los Angeles, California 90033, United States
    Recruiting
    • Clinical Trials Office · Contact323-442-1900
    • Gino In, MD · Principal investigator
  • UCLA
    Los Angeles, California 90095, United States
    Recruiting
    • UCLA Clinical Trials Office · Contact310-794-8783
    • Deborah Wong, MD · Principal investigator
  • University of California, Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
    Recruiting
    • Clinical Trials Office · Contact916-703-9184
    • Andrew Birkeland, MD · Principal investigator
  • H. Lee Moffitt Cancer Center and Research Institute, Inc
    Tampa, Florida 33612, United States
    Recruiting
    • Clinical Trials Office · Contact813-945-3563
    • Christine Chung, MD · Principal investigator
  • Dana Farber/Partners Cancer Care Inc
    Boston, Massachusetts 02115, United States
    Recruiting
    • DFCI Clinical Trials Hotline · Contact877-338-7425
    • Michael Dennis, MD · Principal investigator
  • Memorial Sloan Kettering
    New York, New York 10017, United States
    Recruiting
    • · Contact646-608-3759
    • Eric Sherman, MD · Principal investigator
  • Columbia University Herbert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
    Recruiting
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
    Recruiting
    • · Contact980-442-3213
    • Daniel Carrizosa, MD · Principal investigator
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Clinical Trials Office · Contactbrodeurs@upmc.edu · 412-755-2930
    • Dan Zanberg, MD · Principal investigator
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
    Recruiting
    • Brown Health Clinical Trials Office · Contact401-444-5113
    • Ariel Birnbaum, MD · Principal investigator
  • Medical University of South Carolina, Hollings Cancer Center
    Charleston, South Carolina 29425, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Vanderbilt Clinical Research Center · Contact615-322-2312
    • Jennifer Choe, MD, PhD · Principal investigator
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
    Recruiting
    • · Contact(02) 8514 0000
    • Jenny Lee, MBBS, FRACP · Principal investigator
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
    Recruiting
    • · Contact+61 2 40143590
    • Fiona Day · Principal investigator
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • · Contact+61394965000
    • Alesha Thai, MBBS, FRACP, PhD · Principal investigator
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
    Recruiting
    • · Contact+61 3 8559 5000
    • Danny Rischin, MD · Principal investigator
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • · Contact18007110500
    • Phillippe Bedard, MD · Principal investigator
  • Centre hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec, Canada
    Recruiting
    • · Contact(514) 890-8000
    • Antoine Desilets, MD · Principal investigator
08

References and documents

Publications

  • Hanna GJ, Zandberg DP, Wong DJ, Sherman E, Sacco AG, Yilmaz E, Hernando-Calvo A, Reiners RD, Bohr D, Salazar RL, O'Connell BC, Raben D, Schulten J, Chung CH, Kaczmar J. Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. J Clin Oncol. 2026 Jun 20;44(18):1697-1708. doi: 10.1200/JCO-25-02027. Epub 2026 May 8. PubMed 42102329 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Oct 2027, 88 months after the start.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's planned 88 months is above that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2026 → Oct 2027 and completion Jun 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Jun 12, 2020
StartActual
Jun 1, 2020
Primary completionEst.
Oct 31, 2027was Dec 2026
CompletionEst.
Mar 30, 2028was Jun 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Canada
Oct 6, 2026
Primary completion
Dec 31, 2026→Oct 31, 2027
Oct 6, 2026
Study completion
Jun 1, 2027→Mar 30, 2028
Oct 6, 2026
Enrollment
292→473
Oct 6, 2026
Site contacts
Changed at 14 sites. See the sites
Show 14 sites
  • Moores Cancer Center UC San Diego Health · La Jolla, United StatesContact d•••@health.ucsd.edu · •••0357→d•••@health.ucsd.edu · •••5354
  • Keck School of Medicine of USC · Los Angeles, United StatesContact added •••1900
  • UCLA · Los Angeles, United StatesContact added •••8783
  • University of California, Davis Comprehensive Cancer Center · Sacramento, United StatesContact none listed→•••9184
  • H. Lee Moffitt Cancer Center and Research Institute, Inc · Tampa, United StatesContact H•••@moffitt.org · •••5554→•••3563
  • Dana Farber/Partners Cancer Care Inc · Boston, United StatesContact person changed (no phone or email listed)
  • Memorial Sloan Kettering · New York, United StatesContact person changed (no phone or email listed)
  • Levine Cancer Institute · Charlotte, United StatesContact •••3213→•••3213Contact added (no phone or email listed)
  • UPMC Hillman Cancer Center · Pittsburgh, United StatesContact b•••@upmc.edu→b•••@upmc.edu · •••2930
  • Rhode Island Hospital · Providence, United StatesContact added •••5113
  • Medical University of South Carolina, Hollings Cancer Center · Charleston, United StatesContact n•••@musc.edu · •••8113→n•••@musc.edu · •••9300
  • Vanderbilt University Medical Center · Nashville, United StatesContact added •••2312
  • Chris O'Brien Lifehouse · Camperdown, AustraliaContact none listed→•••0000
  • Austin Hospital · Heidelberg, AustraliaContact •••5000→•••5000Contact added (no phone or email listed)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added
    Show site
    • Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Canada
    Primary completion Dec 31, 2026→Oct 31, 2027
    Study completion Jun 1, 2027→Mar 30, 2028
    Enrollment 292→473
    Site contacts Changed at 14 sites. See the sites
    Show 14 sites
    • Moores Cancer Center UC San Diego Health · La Jolla, United StatesContact d•••@health.ucsd.edu · •••0357→d•••@health.ucsd.edu · •••5354
    • Keck School of Medicine of USC · Los Angeles, United StatesContact added •••1900
    • UCLA · Los Angeles, United StatesContact added •••8783
    • University of California, Davis Comprehensive Cancer Center · Sacramento, United StatesContact none listed→•••9184
    • H. Lee Moffitt Cancer Center and Research Institute, Inc · Tampa, United StatesContact H•••@moffitt.org · •••5554→•••3563
    • Dana Farber/Partners Cancer Care Inc · Boston, United StatesContact person changed (no phone or email listed)
    • Memorial Sloan Kettering · New York, United StatesContact person changed (no phone or email listed)
    • Levine Cancer Institute · Charlotte, United StatesContact •••3213→•••3213Contact added (no phone or email listed)
    • UPMC Hillman Cancer Center · Pittsburgh, United StatesContact b•••@upmc.edu→b•••@upmc.edu · •••2930
    • Rhode Island Hospital · Providence, United StatesContact added •••5113
    • Medical University of South Carolina, Hollings Cancer Center · Charleston, United StatesContact n•••@musc.edu · •••8113→n•••@musc.edu · •••9300
    • Vanderbilt University Medical Center · Nashville, United StatesContact added •••2312
    • Chris O'Brien Lifehouse · Camperdown, AustraliaContact none listed→•••0000
    • Austin Hospital · Heidelberg, AustraliaContact •••5000→•••5000Contact added (no phone or email listed)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04429542
Lead sponsor
Bicara Therapeutics
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Jun 1, 2020
Primary completion
Oct 31, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

David Bohr
Contact
info@bicara.com
6178000335

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ficerafusp alfa

Start the discussion